There is evidence for the role of vaccinations in triggering the development of fibromyalgia and related syndromes.

PMID: 

Autoimmun Rev. 2008 Oct ;8(1):41-3. Epub 2008 Aug 13. PMID: 18706528

Abstract Title: 

Etiology of fibromyalgia: the possible role of infection and vaccination.

Abstract: 

Fibromyalgia syndrome (FMS), a condition characterized by widespread pain and diffuse tenderness, is considered a multifactorial disorder. FMS is now recognized as one of the"central"pain syndromes. Environmental and genetic factors play a role in the pathogenesis of FMS. Various triggers including trauma and stress as well as infections, may precipitate the development of FMS. Certain infections including hepatitis C virus, HIV and Lyme disease have been temporally associated with the development of FMS. There is some evidence for the possible role of vaccinations in triggering the development of FMS and related syndromes, however this association remains to be established.

read more

This review details some of the caveats in “herd immunity”.

PMID: 

Curr Opin Infect Dis. 2012 Jun ;25(3):243-9. PMID: 22561998

Abstract Title: 

Vaccination and herd immunity: what more do we know?

Abstract: 

PURPOSE OF REVIEW: This review summarizes herd immunity, focusing on conceptual developments with application to vaccination programs.RECENT FINDINGS: The conventional idea of herd immunity is based on the relationship between the transmission dynamics of infectious agents and population immunity. However, there have been some recent conceptual developments in vaccine 'herd immunity' or 'herd protection' that address the complexities of imperfect immunity, heterogeneous populations, nonrandom vaccine uptake and 'freeloaders'. Some vaccines may provide better protection than others; for instance, meningococcal conjugate vaccines are superior to polysaccharide vaccines, as is true of pneumococcal and Haemophilus influenzae type b vaccines. Achieving a very high uptake rate should be the target for certain vaccines, for example, measles vaccine, in order to prevent the disease effectively. Emerging issues, for example, waning of immunity after pertussis vaccination, are fresh challenges.SUMMARY: Herd immunity is a complex issue inherent to a vaccine and the population receiving the vaccine. We have more to learn and apply.

read more

Evaluation of animal studies regarding formaldehyde including all routes of exposure, doses and dosing regimens studied, suggested positive associations between formaldehyde exposure and reproductive toxicity, mostly in males.

PMID: 

Mutat Res. 2011 Nov-Dec;728(3):118-38. Epub 2011 Jul 20. PMID: 21787879

Abstract Title: 

Reproductive and developmental toxicity of formaldehyde: a systematic review.

Abstract: 

Formaldehyde, the recently classified carcinogen and ubiquitous environmental contaminant, has long been suspected of causing adverse reproductive and developmental effects, but previous reviews were inconclusive, due in part, to limitations in the design of many of the human population studies. In the current review, we systematically evaluated evidence of an association between formaldehyde exposure and adverse reproductive and developmental effects, in human populations and in vivo animal studies, in the peer-reviewed literature. The mostly retrospective human studies provided evidence of an association of maternal exposure with adverse reproductive and developmental effects. Further assessment of this association by meta-analysis revealed an increased risk of spontaneous abortion (1.76, 95% CI 1.20-2.59, p=0.002) and of all adverse pregnancy outcomes combined (1.54, 95% CI 1.27-1.88, p

read more

Reporting rates of serious adverse events associated with the yellow fever vaccine were significantly higher among vaccinees aged 60 or older.

PMID: 

Vaccine. 2005 May 9 ;23(25):3256-63. PMID: 15837230

Abstract Title: 

Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events.

Abstract: 

Since 1996, the scientific community has become aware of 14 reports of yellow fever vaccine (YEL)-associated viscerotropic disease (YEL-AVD) cases and four reports of YEL-associated neurotropic disease (YEL-AND) worldwide, changing our understanding of the risks of the vaccine. Based on 722 adverse event reports after YEL submitted to the U.S. Vaccine Adverse Event Reporting System in 1990-2002, we updated the estimates of the age-adjusted reporting rates of serious adverse events, YEL-AVD and YEL-AND. We found that the reporting rates of serious adverse events were significantly higher among vaccinees aged>or =60 years than among those 19-29 years of age (reporting rate ratio = 5.9, 95% CI 1.6-22.2). Yellow fever is a serious and potentially fatal disease. For elderly travelers, the risk for severe illness and death due to yellow fever infection should be balanced against the risk of a serious adverse event due to YEL.

read more

Risk estimates of yellow fever to travelers are extremely difficult to ascertain and reports of severe significant adverse events are linked to the 17D yellow fever vaccine.

PMID: 

Expert Rev Vaccines. 2008 Jul ;7(5):579-87. PMID: 18564013

Abstract Title: 

Yellow fever vaccines and international travelers.

Abstract: 

The growth of air travel has diminished the barriers to the spread of yellow fever, posing a threat to regions that have not previously been reached by the disease but are considered receptive, including the Middle East, coastal East Africa, the Indian subcontinent, Asia and Australia. For many decades, vaccination against yellow fever has been required for travelers entering many countries with receptive mosquito vectors in order to prevent the importation of yellow fever virus from a country that had ongoing transmission. Each year, approximately 9 million tourists travel to countries where yellow fever is endemic; the number of tourists who visit yellow fever-endemic regions within these countries may exceed 3 million. Risk estimates of yellow fever to travelers are extremely difficult to ascertain due to fluctuation of the disease by year and season, incomplete surveillance data, and lack of accurate data regarding vaccine coverage of the local population. The 17D live yellow fever vaccine has been widely acknowledged as one of the most effective and safe vaccines in use. Recently, however, reports of severe and previously unrecognized significant adverse events linked to the 17D vaccine have caused major concern. Some have called for the development of new inactivated yellow fever vaccines for travelers. A new approach for manufacturing the live 17D vaccine involves using a full-length cDNA clone of 17D-204 virus. This new method allows production in a cell culture system and potentially reduces the risk of adventitious viruses and selection of a subpopulation during replication, thereby increasing safety.

read more

There are significantly elevated risks of primarily emergency room visits approximately one to two weeks following 12 and 18 month vaccination.

PMID: 

PLoS One. 2011 ;6(12):e27897. Epub 2011 Dec 12. PMID: 22174753

Abstract Title: 

Adverse events following 12 and 18 month vaccinations: a population-based, self-controlled case series analysis.

Abstract: 

BACKGROUND: Live vaccines have distinct safety profiles, potentially causing systemic reactions one to 2 weeks after administration. In the province of Ontario, Canada, live MMR vaccine is currently recommended at age 12 months and 18 months.METHODS: Using the self-controlled case series design we examined 271,495 12 month vaccinations and 184,312 18 month vaccinations to examine the relative incidence of the composite endpoint of emergency room visits or hospital admissions in consecutive one day intervals following vaccination. These were compared to a control period 20 to 28 days later. In a post-hoc analysis we examined the reasons for emergency room visits and the average acuity score at presentation for children during the at-risk period following the 12 month vaccine.RESULTS: Four to 12 days post 12 month vaccination, children had a 1.33 (1.29-1.38) increased relative incidence of the combined endpoint compared to the control period, or at least one event during the risk interval for every 168 children vaccinated. Ten to 12 days post 18 month vaccination, the relative incidence was 1.25 (95%, 1.17-1.33) which represented at least one excess event for every 730 children vaccinated. The primary reason for increased events was statistically significant elevations in emergency room visits following all vaccinations. There were non-significant increases in hospital admissions. There were an additional 20 febrile seizures for every 100,000 vaccinated at 12 months.CONCLUSIONS: There are significantly elevated risks of primarily emergency room visits approximately one to two weeks following 12 and 18 month vaccination. Future studies should examine whether these events could be predicted or prevented.

read more

There are significantly elevated risks of febrile seizures on the day of receipt of DTP vaccine and 8 to 14 days after the receipt of MMR vaccine.

PMID: 

N Engl J Med. 2001 Aug 30 ;345(9):656-61. PMID: 11547719

Abstract Title: 

The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine.

Abstract: 

BACKGROUND: The administration of the diphtheria and tetanus toxoids and whole-cell pertussis (DTP) vaccine and measles, mumps, and rubella (MMR) vaccine has been associated with adverse neurologic events, including seizures. We studied the relation between these vaccinations and the risk of a first seizure, subsequent seizures, and neurodevelopmental disability in children.METHODS: This cohort study was conducted at four large health maintenance organizations and included reviews of the medical records of children with seizures. We calculated the relative risks of febrile and nonfebrile seizures among 679,942 children after 340,386 vaccinations with DTP vaccine, 137,457 vaccinations with MMR vaccine, or no recent vaccination. Children who had febrile seizures after vaccination were followed to identify the risk of subsequent seizures and other neurologic disabilities.RESULTS: Receipt of DTP vaccine was associated with an increased risk of febrile seizures only on the day of vaccination (adjusted relative risk, 5.70; 95 percent confidence interval, 1.98 to 16.42). Receipt of MMR vaccine was associated with an increased risk of febrile seizures 8 to 14 days after vaccination (relative risk, 2.83; 95 percent confidence interval, 1.44 to 5.55). Neither vaccination was associated with an increased risk of nonfebrile seizures. Analyses of automated data alone gave results similar to the analyses of the data from medical-record reviews. The number of febrile seizures attributable to the administration of DTP and MMR vaccines was estimated to be 6 to 9 and 25 to 34 per 100,000 children, respectively. As compared with other children with febrile seizures that were not associated with vaccination, the children who had febrile seizures after vaccination were not found to be at higher risk for subsequent seizures or neurodevelopmental disabilities.CONCLUSIONS: There are significantly elevated risks of febrile seizures on the day of receipt of DTP vaccine and 8 to 14 days after the receipt of MMR vaccine, but these risks do not appear to be associated with any long-term, adverse consequences.

read more

findings show a positive correlation between the number of vaccine doses administered and the percentage of hospitalizations and deaths.

PMID: 

Hum Exp Toxicol. 2012 Oct ;31(10):1012-21. Epub 2012 Apr 24. PMID: 22531966

Abstract Title: 

Relative trends in hospitalizations and mortality among infants by the number of vaccine doses and age, based on the Vaccine Adverse Event Reporting System (VAERS), 1990-2010.

Abstract: 

In this study, the Vaccine Adverse Event Reporting System (VAERS) database, 1990-2010, was investigated; cases that specified either hospitalization or death were identified among 38,801 reports of infants. Based on the types of vaccines reported, the actual number of vaccine doses administered, from 1 to 8, was summed for each case. Linear regression analysis of hospitalization rates as a function of (a) the number of reported vaccine doses and (b) patient age yielded a linear relationship with r(2) = 0.91 and r(2) = 0.95, respectively. The hospitalization rate increased linearly from 11.0% (107 of 969) for 2 doses to 23.5% (661 of 2817) for 8 doses and decreased linearly from 20.1% (154 of 765) for children aged

read more

11.8% of 110 sudden infant death cases examined in the study occurred in temporal association with hexavalent vaccines.

PMID: 

Curr Med Chem. 2014 Mar ;21(7):941-6. PMID: 24083600

Abstract Title: 

Sudden infant death following hexavalent vaccination: a neuropathologic study.

Abstract: 

We examined a large number of sudden infant death syndrome victims in order to point out a possible causal relationship between a previous hexavalent vaccination and the sudden infant death. We selected 110 cases submitted to in-depth histological examination of the autonomic nervous system and provided with detailed clinical and environmental information. In 13 cases (11.8%) the death occurred in temporal association with administration of the hexavalent vaccine (from 1 to 7 days). In none of these victims congenital developmental alterations of the main nervous structures regulating the vital functions were observed. Only the hypoplasia of the arcuate nucleus was present in 5 cases. In one case in particular an acquired hyperacute encephalitis of the tractus solitarii nucleus was diagnosed in the brainstem. This study does not prove a causal relationship between the hexavalent vaccination and SIDS. However, we hypothesize that vaccine components could have a direct role in sparking off a lethal outcome in vulnerable babies. In conclusion, we sustain the need that deaths occurring in a short space of time after hexavalent vaccination are appropriately investigated and submitted to a post-mortem examination particularly of the autonomic nervous system by an expert pathologist to objectively evaluate the possible causative role of the vaccine in SIDS.

read more

Design a site like this with WordPress.com
Get started